Therapie des hepatozellulären Karzinoms

T. F. Greten; H. E. Blum; M. P. Manns; M. Geissler

doi:10.1055/s-2005-858932

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000094.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Z Gastroenterol 2006; 44(1): 43-49
DOI: 10.1055/s-2005-858932

Übersicht

Therapie des hepatozellulären Karzinoms

Treatment of Hepatocellular CarcinomaT. F. Greten¹ , H. E. Blum² , M. P. Manns¹ , M. Geissler^2, ³

¹Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
²Medizinische Klinik II, Universität Freiburg
³Klinik für Onkologie, Gastroenterologie und Allgemeine Innere Medizin, Städtische Kliniken Esslingen a. N.

Further Information

Publication History

Manuskript eingetroffen: 24.8.2005

Manuskript akzeptiert: 10.11.2005

Publication Date:
05 January 2006 (online)

Also available at

Abstract
Full Text
References

Permissions and Reprints

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist weltweit einer der häufigsten malignen Tumoren mit steigender Inzidenz auch in westlichen Ländern. Das HCC wird typischerweise erst relativ spät im Verlauf diagnostiziert und bis auf wenige Ausnahmen ist die Prognose ungünstig. Potenziell kurative Therapieansätze sind die Tumorresektion und in ausgewählten Fällen die Lebertransplantation. Diese chirurgischen Verfahren kommen aber aufgrund des Tumorstadiums oder der Leberfunktion für einen Großteil der Patienten nicht infrage. Weitere nichtchirurgische Therapieverfahren wie Radiofrequenzthermo- und Kryoablation, Alkohol- oder Säureinjektionen, transarterielle Chemoembolisationen, Strahlentherapie und systemische Chemotherapie können einzeln oder in Kombination in den verschiedenen Stadien der Erkrankung eingesetzt werden, um eine Verlängerung des (rezidivfreien) Überlebens und in wenigen Fällen auch eine Heilung zu erzielen.

Abstract

Hepatocellular carcinoma is one of the most common cancers worldwide. The incidence of this disease is also increasing in the Western world. Typically, HCC is diagnosed when patients have already reached an advanced stage of the disease and the prognosis is poor. Potentially curative treatment options include surgical resection or liver transplantation and can be offered to patients with adequate liver function and tumour stage. Other non-surgical treatment options such as radiofrequency ablation, cryoablation, ethanol or acetic acid injection, transarteriel chemoembolisation radiation therapy and systemic chemotherapy can be offered either alone or in combination to selected groups of patients. These treatments can improve (tumour-free) survival and in a few cases even cure the patient.

Schlüsselwörter

Leber - Chemotherapie - Krebs

Key words

Liver - chemotherapy - cancer

Reference

1 Parkin D M, Bray F, Ferlay J. et al . Estimating the world cancer burden: Globocan 2000. Int J Cancer. 2001; 44 153-156

MissingFormLabel
PubMed Search in Google Scholar
2 Deuffic S, Poynard T, Buffat L. et al . Trends in primary liver cancer. Lancet. 1998; 44 214-215

MissingFormLabel
PubMed Search in Google Scholar
3 El-Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med. 1999; 44 745-750

MissingFormLabel
PubMed Search in Google Scholar
4 Fattovich G, Giustina G, Degos F. et al . Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997; 44 463-472

MissingFormLabel
PubMed Search in Google Scholar
5 Talwalkar J A, Gores G J. Diagnosis and staging of hepatocellular carcinoma. Gastroenterology. 2004; 44 S126-S132

MissingFormLabel
PubMed Search in Google Scholar
6 Marrero J A, Fontana R J, Barrat A. et al . Prognosis of hepatocellular carcinoma: Comparison of 7 staging systems in an American cohort. Hepatology. 2005; 44 707-715

MissingFormLabel
PubMed Search in Google Scholar
7 Okuda K, Ohtsuki T, Obata H. et al . Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer. 1985; 44 918-928

MissingFormLabel
PubMed Search in Google Scholar
8 Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology. 2000; 44 840-845

MissingFormLabel
PubMed Search in Google Scholar
9 Llovet J M, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004; 44 S115-S120

MissingFormLabel
PubMed Search in Google Scholar
10 Kudo M, Chung H, Haji S. et al . Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology. 2004; 44 1396-1405

MissingFormLabel
PubMed Search in Google Scholar
11 Mazzaferro V, Regalia E, Doci R. et al . Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996; 44 693-699

MissingFormLabel
PubMed Search in Google Scholar
12 Villa E, Colantoni A, Camma C. et al . Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems. J Clin Oncol. 2003; 44 441-446

MissingFormLabel
PubMed Search in Google Scholar
13 Schwartz M. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2004; 44 S268-S276

MissingFormLabel
PubMed Search in Google Scholar
14 Schlitt H J, Neipp M, Weimann A. et al . Recurrence patterns of hepatocellular and fibrolamellar carcinoma after liver transplantation. J Clin Oncol. 1999; 44 324-331

MissingFormLabel
PubMed Search in Google Scholar
15 Jonas S, Bechstein W O, Steinmuller T. et al . Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology. 2001; 44 1080-1086

MissingFormLabel
PubMed Search in Google Scholar
16 Shetty K, Timmins K, Brensinger C. et al . Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004; 44 911-918

MissingFormLabel
PubMed Search in Google Scholar
17 Seufferlein T, Rozengurt E. Rapamycin inhibits constitutive p70s6 k phosphorylation, cell proliferation, and colony formation in small cell lung cancer cells. Cancer Res. 1996; 44 3895-3897

MissingFormLabel
PubMed Search in Google Scholar
18 Bruix J, Castells A, Bosch J. et al . Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology. 1996; 44 1018-1022

MissingFormLabel
PubMed Search in Google Scholar
19 Jaeck D, Bachellier P, Oussoultzoglou E. et al . Surgical resection of hepatocellular carcinoma. Post-operative outcome and long-term results in Europe: an overview. Liver Transpl. 2004; 44 S58-S63

MissingFormLabel
PubMed Search in Google Scholar
20 Llovet J M, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology. 1999; 44 1434-1440

MissingFormLabel
PubMed Search in Google Scholar
21 Schwartz J D, Schwartz M, Mandeli J. et al . Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol. 2002; 44 593-603

MissingFormLabel
PubMed Search in Google Scholar
22 Lencioni R, Cioni D, Crocetti L. et al . Percutaneous ablation of hepatocellular carcinom: a state-of-the-art. Liver Transpl. 2004; 44 S91-S97

MissingFormLabel
PubMed Search in Google Scholar
23 Omata M, Tateishi R, Yoshida H. et al . Treatment of hepatocellular carcinoma by percutaneous tumor ablation methods: Ethanol injection therapy and radiofrequency ablation. Gastroenterology. 2004; 44 S159-S166

MissingFormLabel
PubMed Search in Google Scholar
24 Lencioni R, Cioni D, Crocetti L. et al . Early-stage hepatocellular carcinoma in patients with cirrhosis: long-term results of percutaneous image-guided radiofrequency ablation. Radiology. 2005; 44 961-967

MissingFormLabel
PubMed Search in Google Scholar
25 Beaugrand M, N’Kontchou G, Seror O. et al . Local/regional and systemic treatments of hepatocellular carcinoma. Semin Liver Dis. 2005; 44 201-211

MissingFormLabel
Thieme Connect PubMed Search in Google Scholar
26 Livraghi T, Giorgio A, Marin G. et al . Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology. 1995; 44 101-108

MissingFormLabel
PubMed Search in Google Scholar
27 Allgaier H P, Deibert P, Olschewski M. et al . Survival benefit of patients with inoperable hepatocellular carcinoma treated by a combination of transarterial chemoembolization and percutaneous ethanol injection-a single-center analysis including 132 patients. Int J Cancer. 1998; 44 601-605

MissingFormLabel
PubMed Search in Google Scholar
28 Livraghi T, Benedini V, Lazzaroni S. et al . Long term results of single session percutaneous ethanol injection in patients with large hepatocellular carcinoma. Cancer. 1998; 44 48-57

MissingFormLabel
PubMed Search in Google Scholar
29 Lin S M, Lin C J, Lin C C. et al . Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma < or = 4 cm. Gastroenterology. 2004; 44 1714-1723

MissingFormLabel
PubMed Search in Google Scholar
30 Sala M, Llovet J M, Vilana R. et al . Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology. 2004; 44 1352-1360

MissingFormLabel
PubMed Search in Google Scholar
31 Lencioni R A, Allgaier H P, Cioni D. et al . Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology. 2003; 44 235-240

MissingFormLabel
PubMed Search in Google Scholar
32 Lin S M, Lin C J, Lin C C. et al . Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut. 2005; 44 1151-1156

MissingFormLabel
PubMed Search in Google Scholar
33 Lo C M, Ngan H, Tso W K. et al . Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002; 44 1164-1171

MissingFormLabel
PubMed Search in Google Scholar
34 Llovet J M, Real M I, Montana X. et al . Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002; 44 1734-1739

MissingFormLabel
PubMed Search in Google Scholar
35 Kawai S, Tani M, Okamura J. et al . Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma - a comparison between L-TAE with farmorubicin and L-TAE with adriamycin: preliminary results (second cooperative study). Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol. 1994; 44 S97-S102

MissingFormLabel
PubMed Search in Google Scholar
36 Bruix J, Sala M, Llovet J M. Chemoembolization for hepatocellular carcinoma. Gastroenterology. 2004; 44 S179-S188

MissingFormLabel
PubMed Search in Google Scholar
37 A c omparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. Groupe d’Etude et de Traitement du Carcinome Hepatocellulaire. N Engl J Med. 1995; 44 1256-1261

MissingFormLabel
PubMed Search in Google Scholar
38 Fuss M, Salter B J, Herman T S. et al . External beam radiation therapy for hepatocellular carcinoma: potential of intensity-modulated and image-guided radiation therapy. Gastroenterology. 2004; 44 S206-S217

MissingFormLabel
PubMed Search in Google Scholar
39 Seong J, Keum K C, Han K H. et al . Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 1999; 44 393-397

MissingFormLabel
PubMed Search in Google Scholar
40 De Ruyck K, Lambert B, Bacher K. et al . Biologic dosimetry of 188Re-HDD/lipiodol versus 131I-lipiodol therapy in patients with hepatocellular carcinoma. J Nucl Med. 2004; 44 612-618

MissingFormLabel
PubMed Search in Google Scholar
41 Kennedy A S, Nutting C, Coldwell D. et al . Pathologic response and microdosimetry of (90)Y microspheres in man: review of four explanted whole livers. Int J Radiat Oncol Biol Phys. 2004; 44 1552-1563

MissingFormLabel
PubMed Search in Google Scholar
42 Ganne-Carrie N, Trinchet J C. Systemic treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2004; 44 275-281

MissingFormLabel
PubMed Search in Google Scholar
43 Schachschal G, Lochs H, Plauth M. Controlled clinical trial of doxorubicin and tamoxifen versus tamoxifen monotherapy in hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2000; 44 281-284

MissingFormLabel
PubMed Search in Google Scholar
44 Kubicka S, Rudolph K L, Tietze M K. et al . Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology. 2001; 44 783-789

MissingFormLabel
PubMed Search in Google Scholar
45 Lai C L, Wu P C, Chan G C. et al . Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer. 1988; 44 479-483

MissingFormLabel
PubMed Search in Google Scholar
46 Thomas M B, Zhu A X. Hepatocellular carcinoma: the need for progress. J Clin Oncol. 2005; 44 2892-2899

MissingFormLabel
PubMed Search in Google Scholar
47 Patt Y Z, Hassan M M, Lozano R D. et al . Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2 b for treatment of hepatocellular carcinoma. J Clin Oncol. 2003; 44 421-427

MissingFormLabel
PubMed Search in Google Scholar
48 Stuart K, Tessitore J, Rudy J. et al . A Phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer. 1999; 44 410-414

MissingFormLabel
PubMed Search in Google Scholar
49 Barbare J C, Bouche O, Bonnetain F. et al . Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma. J Clin Oncol. 2005; 44 4338-4346

MissingFormLabel
PubMed Search in Google Scholar
50 Nowak A K, Chow P K, Findlay M. Systemic therapy for advanced hepatocellular carcinoma: a review. Eur J Cancer. 2004; 44 1474-1484

MissingFormLabel
PubMed Search in Google Scholar
51 Kouroumalis E, Skordilis P, Thermos K. et al . Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut. 1998; 44 442-447

MissingFormLabel
PubMed Search in Google Scholar
52 Yuen M F, Poon R T, Lai C L. et al . A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology. 2002; 44 687-691

MissingFormLabel
PubMed Search in Google Scholar
53 Allgaier H P, Becker G, Olschewski M. et al . Octreotide treatment in patients with advanced hepatocellular carcinoma: First results of the randomized placebo-controlled double-blind HECTOR trial. Hepatology. 2003; 44 760A

MissingFormLabel
PubMed Search in Google Scholar
54 Patt Y Z, Hassan M M, Lozano R D. et al . Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 2005; 44 749-755

MissingFormLabel
PubMed Search in Google Scholar
55 Llovet J M, Sala M, Castells L. et al . Randomized controlled trial of interferon treatment for advanced hepatocellular carcinoma. Hepatology. 2000; 44 54-58

MissingFormLabel
PubMed Search in Google Scholar
56 Kawata S, Yamasaki E, Nagase T. et al . Effect of pravastatin on survival in patients with advanced hepatocellular carcinoma. A randomized controlled trial. Br J Cancer. 2001; 44 886-891

MissingFormLabel
PubMed Search in Google Scholar
57 Butterfield L H. Immunotherapeutic strategies for hepatocellular carcinoma. Gastroenterology. 2004; 44 S232-S241

MissingFormLabel
PubMed Search in Google Scholar
58 Wada Y, Nakashima O, Kutami R. et al . Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration. Hepatology. 1998; 44 407-414

MissingFormLabel
PubMed Search in Google Scholar
59 Takayama T, Sekine T, Makuuchi M. et al . Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet. 2000; 44 802-807

MissingFormLabel
PubMed Search in Google Scholar
60 Greten T F. Antibody therapy for the treatment of colon cancer. Z Gastroenterol. 2004; 44 1413-1415

MissingFormLabel
Thieme Connect PubMed Search in Google Scholar
61 Llovet J M, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet. 2003; 44 1907-1917

MissingFormLabel
PubMed Search in Google Scholar

PD Dr. Tim F. Greten

Abt. Gastroenterologie, Hepatologie und Endoskrinologie, Medizinische Hochschule Hannover

Carl-Neuberg-Str. 1

30625 Hannover

Email: greten.tim@mh-hannover.de